Aimee Merino is an Oncology physician affiliated with University of Minnesota. OpenAlex indexes 31 publications with 663 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202530 payments$60,146openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202575 payments$55,681openpaymentsdata.cms.gov ↗
- Legend Biotech USA Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Understanding and improving responses to adaptive NK cell therapy for leukemia and multiple myeloma
University of Minnesota
FY2025$149,059K08CA255426 - Understanding and improving responses to adaptive NK cell therapy for leukemia and multiple myeloma
University of Minnesota
FY2024$149,059K08CA255426 - Understanding and improving responses to adaptive NK cell therapy for leukemia and multiple myeloma
University of Minnesota
FY2023$148,665K08CA255426
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- B7-H3 expression affects outcomes in myeloma and is targetable with an NK cell engager
Blood Immunology & Cellular Therapy
2026 - B7-H3 is Associated with Worse Outcomes in Newly Diagnosed Myeloma and Can Be Targeted with a Tri-Specific Killer Engager
Clinical Lymphoma Myeloma & Leukemia
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Jay Cohn, MD
University of Minnesota
Douglas Yee, MD
University of Minnesota
David Benditt, MD
University of Minnesota
Stuart Grossman, MD
University of Minnesota
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”